SSA Seeks Industry Help In Speeding Coverage For Orphan Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Sponsors of drugs to treat disabling illnesses have an opportunity to work with the Social Security Administration to simplify eligibility determinations that could in turn make it easier for patients to obtain Medicare coverage for their treatments.
You may also be interested in...
Health Reform And Rare Diseases: Orphan Drugs May Do Well Amid Changes
Advocates for patients with rare diseases are urging Congress to build in special considerations for treatments for rare diseases in several key provisions of health care reform
Health Reform And Rare Diseases: Orphan Drugs May Do Well Amid Changes
Advocates for patients with rare diseases are urging Congress to build in special considerations for treatments for rare diseases in several key provisions of health care reform
FDA Urged To Improve “Predictability” For Orphan Drugs By Social Security Head Astrue
Commissioner Hamburg urged to set regular briefings on orphan drug development. Policy at the top doesn’t always translate into the “trenches,” former TKT CEO says.